Indian pharma stocks, including Sun Pharmaceutical Industries, Gland Pharma, Lupin and others traded sharply lower on Wednesday after the US President Donald Trump said he will soon announce a ...

Mumbai's Lupin has issued a voluntary recall of 2,724 bottles of the tricyclic antidepressant clomiPRAMINE hydrochloride, ...

Dr Reddy's Laboratories and Lupin are recalling products from the US market due to labelling and manufacturing issues. Dr ...

Tolvaptan is indicated to slow kidney function decline in adults at risk of rapidly progressing autosomal dominant polycystic kidney disease.

Zydus Lifesciences and Lupin are unlikely to face significant valuation impacts despite a US court ruling against them in a patent dispute over the generic version of Astellas Pharma Inc.'s ...

Indian pharmaceutical stocks experienced a significant decline. This followed US President Donald Trump's executive order.

NASHVILLE, Tenn., April 29, 2025 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (Nasdaq: CPIX), a specialty pharmaceutical company, announced today that it will release its first quarter 2025 ...

Lupin gains US FDA approval for Tolvaptan tablets in various dosages, marking a significant entry into the nephrology market.

Indian pharmaceutical stocks experienced a downturn following Donald Trump's renewed threat to impose tariffs on pharmaceutical imports. The Nifty Pharma index fell by 1.7%, with major companies ...

Jazz Pharmaceuticals (JAZZ) announced that the Committee for Medicinal Products for Human Use of the European Medicines Agency has adopted a positive opinion recommending the conditional marketing ...

DUBLIN, April 30, 2025 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the Company will participate in the BofA Securities 2025 Healthcare Conference. Company ...

Needham analyst Serge Belanger maintained a Buy rating on Pacira Pharmaceuticals (PCRX – Research Report) today and set a price target of $32.00. The company’s shares closed yesterday at $22.91.